Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1.  | 
                ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region | 
                  Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi  | 
                
                
                   View  | 
              
2.  | 
                ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS | 
                  Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE  | 
                
                
                   View  | 
              
3.  | 
                ECCT/25/03/03 | ALIM STUDY Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial. | 
                  Principal Investigator(s) 1. Dr. QUENTIN AWORI Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE  | 
                
                
                   View  | 
              
4.  | 
                ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. | 
                  Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)  | 
                
                
                   View  | 
              
5.  | 
                ECCT/24/07/01 | LCCC 2330 Feasibility of intravaginal artesunate as adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: A Phase II trial | 
                  Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Cervical Cancer Screening Program (CCSP) Lumumba Sub-County Hospital  | 
                
                
                   View  | 
              
